P 960. Intrathecal Administration of Nusinersen in Patients with SMA: Experience and Challenges—A Single-Center Report
Abstract
Backround: Nusinersen (Spinraza) is an antisense oligonucleotid. In October 2016, it became available for the treatment via intrathecal administration for patients with 5q-associated spinal muscular atrophy (SMA) Type 1 in Germany in an early open access program. In May 2017, the medication was approved for all types of 5q-associated...
Paper Details
Title
P 960. Intrathecal Administration of Nusinersen in Patients with SMA: Experience and Challenges—A Single-Center Report
Published Date
Oct 1, 2018
Journal
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History